Pfizer (NYSE:PFE) Shares Up 1.7% – What’s Next?

Pfizer Inc. (NYSE:PFE)’s share price traded up 1.7% during trading on Wednesday . The company traded as high as $29.09 and last traded at $29.0220. 39,035,343 shares traded hands during mid-day trading, a decline of 7% from the average session volume of 41,787,016 shares. The stock had previously closed at $28.55.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer granted Medicus Pharma a global license to develop and commercialize the early-stage CD228V antibody-drug conjugate. The agreement is valued at more than $1 billion, plus royalties, providing potential milestone and royalty revenue while advancing Pfizer’s oncology strategy. Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
• Positive Sentiment: The FDA approved Pfizer’s 2026–2027 COMIRNATY XFG COVID-19 vaccine formula for high-risk age groups. The approval reinforces Pfizer’s vaccine franchise, although the commercial impact may be more limited than during the pandemic. Pfizer After FDA Vaccine Approval Faces A Fair Value Reality Check
• Positive Sentiment: Investors are increasingly focused on Pfizer’s obesity and oncology pipeline, including berobenatide and next-generation cancer medicines intended to support growth from 2028 onward. A new asthma candidate, PF-08103402, has also entered Phase 1 testing, expanding the development pipeline. Pfizer’s Pipeline Strategy Centers on Obesity and Oncology
• Neutral Sentiment: PFE has risen about 25.6% over the past year and recently reached a new 52-week high. Unusually high options volume indicates heightened trading interest, but does not establish a clear fundamental direction. Pfizer Reaches a New 52-Week High
• Negative Sentiment: Several valuation reviews argue that Pfizer may now be fairly valued—or potentially a value trap—after its recent advance. Analysts note that declining legacy and post-pandemic sales, along with future patent-cliff pressure, could make further gains dependent on successful pipeline launches. Pfizer Stock Looks Fully Valued

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on PFE shares. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. Guggenheim lowered their price objective on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a report on Friday, August 7th. BMO Capital Markets reduced their target price on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $28.28.

Pfizer Stock Performance

The stock’s fifty day moving average price is $25.90 and its 200-day moving average price is $26.33. The company has a market capitalization of $164.26 billion, a P/E ratio of 37.92, a PEG ratio of 1.95 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. The company had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company’s revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th were given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.0%. The ex-dividend date of this dividend was Friday, July 24th. Pfizer’s payout ratio is presently 226.32%.

Hedge Funds Weigh In On Pfizer

Hedge funds have recently bought and sold shares of the business. Evolution Wealth Management Inc. raised its position in shares of Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 566 shares in the last quarter. Godfrey Financial Associates Inc. bought a new position in Pfizer during the 4th quarter worth $26,000. Keb Asset Management LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at $26,000. HFM Investment Advisors LLC grew its holdings in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares in the last quarter. Finally, Field & Main Bank bought a new position in shares of Pfizer in the second quarter worth $27,000. 68.36% of the stock is owned by institutional investors.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.